Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
KOOL's Cash to Debt is ranked higher than
94% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. KOOL: No Debt )
Ranked among companies with meaningful Cash to Debt only.
KOOL' s 10-Year Cash to Debt Range
Min: 0.87  Med: 1499.96 Max: No Debt
Current: No Debt
Equity to Asset 0.69
KOOL's Equity to Asset is ranked higher than
57% of the 280 Companies
in the Global Medical Devices industry.

( Industry Median: 0.66 vs. KOOL: 0.69 )
Ranked among companies with meaningful Equity to Asset only.
KOOL' s 10-Year Equity to Asset Range
Min: 0.45  Med: 0.81 Max: 0.91
Current: 0.69
0.45
0.91
Interest Coverage No Debt
KOOL's Interest Coverage is ranked higher than
90% of the 167 Companies
in the Global Medical Devices industry.

( Industry Median: 10000.00 vs. KOOL: No Debt )
Ranked among companies with meaningful Interest Coverage only.
KOOL' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: -3.11
M-Score: -2.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -97.39
KOOL's Operating margin (%) is ranked lower than
77% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. KOOL: -97.39 )
Ranked among companies with meaningful Operating margin (%) only.
KOOL' s 10-Year Operating margin (%) Range
Min: -211.11  Med: -53.78 Max: -12.12
Current: -97.39
-211.11
-12.12
Net-margin (%) -94.88
KOOL's Net-margin (%) is ranked lower than
76% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.99 vs. KOOL: -94.88 )
Ranked among companies with meaningful Net-margin (%) only.
KOOL' s 10-Year Net-margin (%) Range
Min: -213.33  Med: -50.98 Max: -10.97
Current: -94.88
-213.33
-10.97
ROE (%) -35.84
KOOL's ROE (%) is ranked lower than
73% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. KOOL: -35.84 )
Ranked among companies with meaningful ROE (%) only.
KOOL' s 10-Year ROE (%) Range
Min: -162.6  Med: -31.29 Max: -13.56
Current: -35.84
-162.6
-13.56
ROA (%) -27.54
KOOL's ROA (%) is ranked lower than
70% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: -0.33 vs. KOOL: -27.54 )
Ranked among companies with meaningful ROA (%) only.
KOOL' s 10-Year ROA (%) Range
Min: -106.67  Med: -25.91 Max: -10.6
Current: -27.54
-106.67
-10.6
ROC (Joel Greenblatt) (%) -237.42
KOOL's ROC (Joel Greenblatt) (%) is ranked lower than
73% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. KOOL: -237.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
KOOL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -231.71  Med: -153.65 Max: -36.5
Current: -237.42
-231.71
-36.5
Revenue Growth (3Y)(%) -25.20
KOOL's Revenue Growth (3Y)(%) is ranked lower than
90% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. KOOL: -25.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
KOOL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -25.2  Med: -2.10 Max: 20.4
Current: -25.2
-25.2
20.4
EBITDA Growth (3Y)(%) 27.30
KOOL's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. KOOL: 27.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
KOOL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -38.9  Med: -10.55 Max: 100
Current: 27.3
-38.9
100
EPS Growth (3Y)(%) 28.40
KOOL's EPS Growth (3Y)(%) is ranked higher than
81% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: -1.60 vs. KOOL: 28.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
KOOL' s 10-Year EPS Growth (3Y)(%) Range
Min: -36.4  Med: -7.65 Max: 114.8
Current: 28.4
-36.4
114.8
» KOOL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

KOOL Guru Trades in Q2 2013

Jim Simons 191,000 sh (+2.85%)
» More
Q3 2013

KOOL Guru Trades in Q3 2013

Jim Simons 222,000 sh (+16.23%)
» More
Q4 2013

KOOL Guru Trades in Q4 2013

Jim Simons 187,700 sh (-15.45%)
» More
Q1 2014

KOOL Guru Trades in Q1 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with KOOL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.67
KOOL's P/B is ranked higher than
96% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 3.18 vs. KOOL: 0.67 )
Ranked among companies with meaningful P/B only.
KOOL' s 10-Year P/B Range
Min: 0.62  Med: 1.75 Max: 20.7
Current: 0.67
0.62
20.7
P/S 1.48
KOOL's P/S is ranked higher than
69% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. KOOL: 1.48 )
Ranked among companies with meaningful P/S only.
KOOL' s 10-Year P/S Range
Min: 0.56  Med: 1.91 Max: 26.07
Current: 1.48
0.56
26.07
EV-to-EBIT -1.30
KOOL's EV-to-EBIT is ranked lower than
241% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 22.74 vs. KOOL: -1.30 )
Ranked among companies with meaningful EV-to-EBIT only.
KOOL' s 10-Year EV-to-EBIT Range
Min: -49.4  Med: -4.60 Max: 0.5
Current: -1.3
-49.4
0.5
Current Ratio 1.87
KOOL's Current Ratio is ranked lower than
67% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. KOOL: 1.87 )
Ranked among companies with meaningful Current Ratio only.
KOOL' s 10-Year Current Ratio Range
Min: 1.52  Med: 5.11 Max: 16.85
Current: 1.87
1.52
16.85
Quick Ratio 1.27
KOOL's Quick Ratio is ranked lower than
71% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.02 vs. KOOL: 1.27 )
Ranked among companies with meaningful Quick Ratio only.
KOOL' s 10-Year Quick Ratio Range
Min: 0.86  Med: 3.55 Max: 15.88
Current: 1.27
0.86
15.88
Days Inventory 173.67
KOOL's Days Inventory is ranked lower than
65% of the 280 Companies
in the Global Medical Devices industry.

( Industry Median: 130.93 vs. KOOL: 173.67 )
Ranked among companies with meaningful Days Inventory only.
KOOL' s 10-Year Days Inventory Range
Min: 114.21  Med: 145.93 Max: 256.49
Current: 173.67
114.21
256.49
Days Sales Outstanding 128.99
KOOL's Days Sales Outstanding is ranked lower than
85% of the 274 Companies
in the Global Medical Devices industry.

( Industry Median: 68.45 vs. KOOL: 128.99 )
Ranked among companies with meaningful Days Sales Outstanding only.
KOOL' s 10-Year Days Sales Outstanding Range
Min: 54.35  Med: 96.36 Max: 124.63
Current: 128.99
54.35
124.63

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 10.33
KOOL's Price/Tangible Book is ranked lower than
80% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. KOOL: 10.33 )
Ranked among companies with meaningful Price/Tangible Book only.
KOOL' s 10-Year Price/Tangible Book Range
Min: 0.64  Med: 5.88 Max: 65
Current: 10.33
0.64
65
Price/Median PS Value 0.78
KOOL's Price/Median PS Value is ranked higher than
75% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 1.11 vs. KOOL: 0.78 )
Ranked among companies with meaningful Price/Median PS Value only.
KOOL' s 10-Year Price/Median PS Value Range
Min: 0.29  Med: 3.53 Max: 12.93
Current: 0.78
0.29
12.93
Earnings Yield (Greenblatt) (%) -76.71
KOOL's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.80 vs. KOOL: -76.71 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
KOOL' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -76.71  Med: 148.30 Max: 3993.9
Current: -76.71
-76.71
3993.9

Analyst Estimate

Jun15 Jun16 Jun17 Jun18
Revenue(Mil) 17 17 76 150
EPS($) -0.42 -0.35 -0.03 0.31
EPS without NRI($) -0.42 -0.35 -0.03 0.31

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:THRA.Germany,
Cesca Therapeutics Inc., formerly known as ThermoGenesis Corp, founded in 1986 in California. The Company is engaged in the research, development, and commercialization of cell-based therapeutics for use in regenerative medicine. It serves patients, physicians and partners through cellular therapeutics, medical/diagnostic device development and commercialization, and cell manufacturing and banking markets. The Company offers SurgWerks, a therapeutic technology platform, in various stages of clinical trials as a potential treatment for acute myocardial infarction, critical limb ischemia, and orthopedic injuries. It also offers CellWerks, an indication-specific device/protocol program for select applications in umbilical cord blood banking, bone marrow transplantation, and regenmed bioprocess markets. The Company complies under a variety of Good practices concerning operation of clinical cell manufacturing, processing, testing, and storage facilities, as well as patient safety, quality laboratory documentation, and quality cell processing and handling. It supports production of personalized medicine prescriptions and large scale batch processes. The Company has the ability to support various device prototyping and validation, typically required in a combination product. Its clinical research organization is specialized, in-hospital and cell therapy CRO.
» More Articles for KOOL

Headlines

Articles On GuruFocus.com
comment on KOOL Dec 01 2011 
comment on KOOL Aug 26 2011 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 11 2011 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 09 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares Sep 28 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares May 12 2009 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
CESCA THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 29 2015
CESCA THERAPEUTICS REPORTS THIRD QUARTER FISCAL 2015 RESULTS Jun 29 2015
CESCA THERAPEUTICS INC. Financials Jun 27 2015
10-Q for Cesca Therapeutics, Inc. Jun 26 2015
10-Q for Cesca Therapeutics, Inc. Jun 25 2015
CESCA THERAPEUTICS INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Jun 25 2015
Cesca Therapeutics Announces Compliance With Nasdaq Stock Market Under Listing Rule 5250(c)(1) Jun 25 2015
CESCA THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report Jun 24 2015
Cesca Therapeutics gets patent, approval to start clinical trial Jun 23 2015
CESCA THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jun 23 2015
Cesca Therapeutics Reports Third Quarter Fiscal 2015 Results Jun 23 2015
Cesca Therapeutics Announces Issuance of New U.S. Patent Jun 23 2015
Q3 2015 Cesca Therapeutics Inc Earnings Release - Time Not Supplied Jun 23 2015
Cesca Therapeutics Announces Issuance of New U.S. Patent Jun 23 2015
CESCA THERAPEUTICS TO ANNOUNCE THIRD QUARTER FISCAL 2015 RESULTS ON JUNE 23, 2015 Jun 17 2015
Cesca Therapeutics to Announce Third Quarter Fiscal 2015 Results on June 23, 2015 Jun 17 2015
Cesca Therapeutics Receives FDA IDE Approval for U.S. Pivotal Clinical Trial in Critical Limb... Jun 16 2015
CESCA THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jun 15 2015
Cesca's interim CEO takes permanent position as company faces challenges Jun 12 2015
CESCA THERAPEUTICS BOARD OF DIRECTORS APPOINT ROBIN C. STRACEY AS CHIEF EXECUTIVE OFFICER Jun 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK